Abstracts tagged "autoimmune diseases"

Abstract Number: 374 • 2019 ACR/ARP Annual Meeting
The INBUILD Trial of Nintedanib in Patients with Progressive Fibrosing Interstitial Lung Diseases: Subgroup with Autoimmune Diseases
Eric Matteson¹, Clive Kelly ², Jörg Distler ³, Anna Maria Hoffmann-Vold ⁴, James Seibold ⁵, Shikha Mittoo ⁶, Oliver Distler ⁷, Rainer-Georg Goeldner ⁸, Rozsa Schlenker-Herceg ⁹, Susanne Stowasser ¹⁰, Manuel Quaresma ¹⁰ and Kevin Flaherty ¹¹, ¹Mayo Clinic College of Medicine and Science, Rochester, Minnesota, USA, Rochester, ²Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, UK, Newcastle, United Kingdom, ³Department of Internal Medicine 3 – Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg (FAU) and University Hospital Erlangen, Erlangen, Germany, Erlangen, Germany, ⁴Department of Rheumatology, Oslo University Hospital, Oslo, Norway, Oslo, Norway, ⁵Scleroderma Research Consultants LLC, Aiken, South Carolina, USA, Aiken, ⁶University Health Network, Toronto, Ontario, Canada, Toronto, Canada, ⁷Dept. of Rheumatology, University Hospital Zürich, Zürich, Switzerland, Zürich, Switzerland, ⁸Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany, Biberach, Germany, ⁹Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, Connecticut, USA, Ridgefield, ¹⁰Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany, Ingelheim am Rhein, Germany, ¹¹University of Michigan, Ann Arbor, Michigan, USA, Ann Arbor, MI
Background/Purpose: Some patients with autoimmune disease develop progressive fibrosing interstitial lung disease (ILD) characterized by increasing fibrosis on HRCT, decline in lung function, worsening symptoms…
Abstract Number: 2033 • 2019 ACR/ARP Annual Meeting
IRAK4 Inhibition Suppresses TLR7, TLR9, and SLE Serum-Induced IFNA Production in Primary Human Plasmacytoid Dendritic Cells
Angie Hammond¹, Sean Parghi ¹, Nathan Wright ¹, Ethan Grant ¹, James Taylor ¹ and Matthew Warr ¹, ¹Gilead Sciences, Inc., Foster City, CA
Background/Purpose: A hallmark of lupus is the presence of antinuclear autoantibodies, including those against RNA-protein complexes and double-stranded DNA (dsDNA).1,2 FcγR-mediated internalization of these nucleic…
Abstract Number: 712 • 2019 ACR/ARP Annual Meeting
Safety and Tolerability of Nintedanib in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease in the SENSCIS Trial: Subgroup Analysis Based on Demographic Characteristics
Oliver Distler¹, Kristin Highland ², Maureen Mayes ³, Masataka Kuwana ⁴, Lesley Saketkoo ⁵, Madelon Vonk ⁶, Michael Kreuter ⁷, Laura Hummers ⁸, Ute von Wangenheim ⁹, Martina Gahlemann ¹⁰, Veronika Kohlbrenner ¹¹, Margarida Alves ¹², Emmanuelle Clerisme-Beaty ¹² and Arata Azuma ¹³, ¹Dept. of Rheumatology, University Hospital Zürich, Zürich, Switzerland, Zürich, Switzerland, ²Cleveland Clinic, Cleveland, Ohio, USA, Cleveland, OH, ³Division of Rheumatology and Clinical Immunogenetics, University of Texas McGovern Medical School, Houston, Texas, USA, Houston, TX, ⁴Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, Tokyo, Japan, Bunkyo-ku, Tokyo, Japan, ⁵New Orleans Scleroderma and Sarcoidosis Patient Care and Research Center, New Orleans; Tulane University School of Medicine, University Medical Center – Comprehensive Pulmonary Hypertension Center, USA, New Orleans, ⁶Department of Rheumatology, Radboud University Medical Center, Nijmegen, The Netherlands, Nijmegen, Gelderland, Netherlands, ⁷Center for Interstitial and Rare Lung Diseases, Pneumology, Thoraxklinik, University of Heidelberg, Member of the German Center for Lung Research, Germany, Germany, Germany, ⁸Johns Hopkins University School of Medicine, Division of Rheumatology, Baltimore, MD, USA, Baltimore, MD, ⁹Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riss, Germany, Biberach an der Riss, ¹⁰Boehringer Ingelheim (Schweiz) GmbH, Basel, Switzerland, Basel, Switzerland, ¹¹Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USA, Ridgefield, ¹²Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany, Ingelheim am Rhein, Germany, ¹³Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School, Tokyo, Japan, Tokyo, Japan
Background/Purpose: In the SENSCIS trial in patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD), the adverse events associated with nintedanib were manageable for most patients…
Abstract Number: 2075 • 2019 ACR/ARP Annual Meeting
Cross-sectional Study and Mendelian Randomization Analysis of Diet in Six Prevalent Autoimmune Diseases
Antonio Julià¹, Sergio H Martinez ², Jesús Tornero ³, Juan Cañete ⁴, Antonio Fernández-Nebro ⁵, Francisco J. Blanco ⁶, Jesús Rodríguez ⁷, Francisco Javier Lopez-Longo ⁸, Benjamín Fernandez-Gutierrez ⁹, Jordi Gratacós ¹⁰, Jose J Pérez Venegas ¹¹, Carolina Pérez ¹², Ruben Queiró ¹³, Alejandro Olivé-Marqués ¹⁴, Mercedes Alperi-López ¹⁵, Carlos Montilla ¹⁶, José Luís Andreu ¹⁷, Juan Carlos Torre-Alonso ¹⁸, Mª Ángeles Aguirre-Zamorano ¹⁹, Hèctor Corominas ²⁰, Paloma Vela ²¹, Víctor Martínez-Taboada ²², Sara Marique ²³, Joan M Nolla ²⁴, Isidoro Gonzalez ²⁵, Santiago Muñoz-Fernandez ²⁶, José Luís Marenco de la Fuente ²⁷, Carlos González ²⁸, Antonio Zea ²⁹, Maria Lopez Lasanta ³⁰, Daniel Roig ³¹, Jose Maria Pego-Reigosa ³², Mireia Lopez Corbeto ³³, Pedro Zarco ³⁴, Mercedes Freire González ³⁵, Alba Erra ³⁶, Elvira Díez ³⁷, Santos Castañeda ³⁸, Esther Rodriguez ³⁹, Alicia García ⁴⁰, Patricia Carreira ³⁹, Georgina Salvador ⁴¹, Ricardo Blanco ⁴², Cesar Diaz-Torne ⁴³, Alfredo Willisch Domínguez ⁴⁴, Joan Antonio Mosquera ⁴⁵, Simón Sánchez-Fernández ⁴⁶, Júlio Ramírez ⁴⁷ and Sara Marsal ⁴⁸, ¹Rheumatology Research Group, Vall d’Hebron Hospital Research Institute, Barcelona, Spain., Barcelona, Catalonia, Spain, ²Hospital Vall d'Hebron, Barcelona, Barcelona, Spain, ³Hospital Universitario Guadalajara, Guadalajara, Spain., Guadalajara, Castilla-La Mancha, Spain, ⁴Rheumatology Department, Hospital Clínic and IDIBAPS,, Barcelona, Spain, ⁵Hospital Carlos Haya, Malaga, Spain, ⁶Servicio de Reumatología. Instituto de Investigación Biomédica de A Coruña (INIBIC). Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas. Universidade da Coruña (UDC). As Xubias, 15006. A Coruña, España, A Coruña, Spain, ⁷Hospital Universitario de Bellvitge, Hospitalet, Spain, ⁸Hospital Universitario Gregorio Marañón, Madrid, Madrid, Spain, ⁹Hospital Clínico San Carlos, Madrid, Madrid, Spain, ¹⁰Hospital Parc Taulí, Sabadell, Catalonia, Spain, ¹¹Hospital Jerez de la Frontera, Jerez de la Frontera, Spain, ¹²Parc de Salut Mar, Barcelona, Barcelona, Spain, ¹³Hospital Universitario Central de Asturias, Oviedo, Oviedo, Spain, ¹⁴Hospital Universitari Germans Trias i Pujol, Badalona, Catalonia, Spain, ¹⁵Hospital Universitario Central de Asturias, Oviedo, Spain, ¹⁶Hospital Clínico Universitario de Salamanca, Salamanca, Spain, ¹⁷Hospital Puerta de Hierro, Madrid, Madrid, Spain, ¹⁸Hospital Monte Naranco, Oviedo, Spain, ¹⁹IMIBIC/Reina Sofia Hospital/University of Cordoba, Córdoba, Spain, ²⁰Hospital de la Santa Creu i Sant Pau, Barcelona, Barcelona, Spain, ²¹Hospital General Universitario de Alicante, Alicante, Spain, ²²Hospital Universitario Marqués de Valdecilla, Santander, Spain, ²³Hospital Regional Univeristario de Málaga, Málaga, Spain, ²⁴Hospital Universitari de Bellvitge, Hospitalet, Spain, ²⁵Hospital Universitario La Princesa, Madrid, Spain, ²⁶Hospital Universitario Infanta Sofía, Madrid, Madrid, Spain, ²⁷Hospital Valme, Sevilla, Sevilla, Spain, ²⁸Hospital Universitario Gregorio Marañón, Madrid, Spain, ²⁹Hospital Universitario Ramón y Cajal, Madrid, Madrid, Spain, ³⁰Hospital Universitari Vall Hebrón, Barcelona, Barcelona, Catalonia, Spain, ³¹Hospital Moisès Broggi, Barcelona, Sant Joan Despí, Barcelona, Singapore, ³²Complexo Hospitalario Universitario, Vigo, Spain, ³³Hospital Universitari Vall d'Hebron, Barcelona, Catalonia, Spain, ³⁴Hospital Universitario Fundación Alcorcón, Madrid, Madrid, Spain, ³⁵Hospital Universitario Juan Canalejo, La Coruña, Spain, ³⁶H Sant Rafael, Barcelona, Barcelona, Spain, ³⁷Complejo Asistencial Universitario de León, León, Castilla y Leon, Spain, ³⁸Rheumatology, Hospital Universitario La Princesa, Madrid, Madrid, Spain, ³⁹Hospital Universitario 12 de Octubre, Madrid, Spain, ⁴⁰Centro de Salud Virgen de los Reyes, Sevilla, Sevilla, Spain, ⁴¹Hospital Mútua Terrassa, Terrassa, Spain, ⁴²Hospital Universitario Marqués de Valdecilla, Santander, Cantabria, Spain, ⁴³Hospital de la Santa Creu i Sant Pau, barcelona, Catalonia, Spain, ⁴⁴Complexo Hospitalario de Ourense, Ourense, Spain, ⁴⁵Complejo Hospitalario Hospital Provincial de Pontevedra, Pontevedra, Spain, ⁴⁶Hospital La Mancha Centro, Alcázar de San Juan, Alcázar de San Juan, Spain, ⁴⁷Hospital Clínic de Barcelona, Barcelona, Spain, ⁴⁸Vall d’Hebron Hospital, Barcelona, Catalonia, Spain
Background/Purpose: Autoimmune diseases (AD) are complex diseases associated with both genetic and environmental risk factors. In the last 10 years major advances have been made…
Abstract Number: 826 • 2019 ACR/ARP Annual Meeting
Immune-Mediated Inflammatory Diseases (IMID) Collectively Rank Among the Leading Causes of Death
Meifang Wu¹, Eric Yen ² and Ram Raj Singh ², ¹UCLA David Geffen School of Medicine, Los Angeles, CA, ²UCLA, Los Angeles
Background/Purpose: Almost every organ system can be affected by primary immune-mediated diseases characterized by inflammation and therapeutic response to immune-suppressive or anti-inflammatory drugs. These diseases…
Abstract Number: 2114 • 2019 ACR/ARP Annual Meeting
Risk Factors for Cytomegalovirus Infection in Patients with Autoimmune Diseases
Daisuke Kobayashi¹, Sayuri Takamura ², Yoko Wada ³, Takeshi Kuroda ⁴ and Ichiei Narita ¹, ¹Division of Clinical Nephrology and Rheumatology, Niigata University, Niigata, Niigata, Japan, ²Division of Clinical Nephrology and Rheumatology, Niigata University, Niigata, Japan, ³Niigata Rinko Hospital, Niigata, Niigata, Japan, ⁴Health administration office, Niigata University, Niigata, Niigata, Japan
Background/Purpose: Intensive immunosuppressive treatment is often required for patients with autoimmune diseases, and those who are thus treated have a high risk of opportunistic infections.…
Abstract Number: 880 • 2019 ACR/ARP Annual Meeting
Diseased Lupus Nephritis Kidneys Serve as a Primary Site of Systemic Autoimmune Development
Matthew Woodruff¹, Christopher Tipton ¹, Jennifer Hom ¹ and Iñaki Sanz ¹, ¹Emory University, Atlanta, GA
Background/Purpose: Lupus nephritis (LN) is an autoimmune destruction of the kidney glomeruli and loss of kidney function affecting almost half of lupus patients. Although the…
Abstract Number: 2150 • 2019 ACR/ARP Annual Meeting
Frequency of Polyautoimmunity in a Tertiary Hospital
Elena Grau García¹, José Ivorra Cortés ¹, Jorge Juan Fragio Gil ¹, Roxana Gonzalez Mazarío ¹, Marta de la Rubia Navarro ¹, Cristóbal Pavez Perales ¹, Cristina Alcañiz Escandell ¹, Inmaculada Chalmeta Verdejo ¹, Luis González Puig ¹, Isabel Martínez Cordellat ¹, Rosa Negueroles Albuixech ¹, José Eloy Oller Rodríguez ², Francisco Miguel Ortiz-Sanjuán ¹, Elvira Vicens Bernabeu ¹, Carmen Nájera Herranz ¹, Inés Cánovas Olmos ¹, Samuel Leal Rodriguez ¹ and José Andrés Román Ivorra ¹, ¹Rheumatology Department. HUP La Fe, Valencia, Comunidad Valenciana, Spain, ²Rheumatology Department. HUP La Fe, v, Comunidad Valenciana, Spain
Background/Purpose: Polyautoimmunity (PAI) is the presence of more than one Autoimmune Disease (AID) in one patient. PAI have been reported in different AIDs as systemic…
Abstract Number: 1076 • 2019 ACR/ARP Annual Meeting
Incidence of Non-serious Infections Among Live Born Infants Born to Mothers Who Used Biologic Medications During Pregnancy for the Treatment of Autoimmune Diseases
Christina Chambers¹, Yunjun Luo ², Diana L. Johnson ², Kenneth Lyons Jones ² and Ronghui Xu ², ¹University of California San Diego, La Jolla, ²University of California, San Diego, La Jolla
Background/Purpose: In infants whose mothers were treated with biologic therapies during pregnancy, there has been a theoretical concern regarding potential risk of infections. Several recent…
Abstract Number: 2155 • 2019 ACR/ARP Annual Meeting
The Spectrum of Interstitial Lung Disease Associated with Autoimmune Diseases: Data of a 3-Year-Prospective Study from a Referral Center of Lung Transplantation
Sara Remuzgo-Martínez¹, Diana Prieto-Peña ², Mónica Calderón-Goercke ², Victor Manuel Mora Cuesta ³, David Iturbe Fernández ¹, Sonia M. Fernández Rozas ³, Jose Manuel Cifrian Martínez ³ and Miguel Angel González-Gay ⁴, ¹Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, IDIVAL, Santander, Spain, Santander, Spain, ²Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, IDIVAL; and Rheumatology Department, Hospital Universitario Marqués de Valdecilla, Santander, Spain, Santander, Spain, ³Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, IDIVAL; and Pneumology Department, Hospital Universitario Marqués de Valdecilla, Santander, Spain, Santander, Spain, ⁴Universidad de Cantabria and IDIVAL, Hospital Universitario Marqués de Valdecilla, Santander, Spain
Background/Purpose: Interstitial lung disease (ILD) occurs in approximately 15% of patients with autoimmune diseases (AD) [1]. Its presence is associated with an increased risk of…
Abstract Number: 1915 • 2018 ACR/ARHP Annual Meeting
Big Data Analysis of Autoimmune Diseases Induced By Cancer Immunotherapies: Identifying Pharmacological Patterns of Organ-Specific Involvement
Soledad Retamozo^1,2,3, Alejandra Flores-Chavez^4,5,6, Belchin Kostov⁷, Antoni Sisó-Almirall⁸, Marta Pérez-de-Lis⁹, Roberto Pérez-Alvarez¹⁰, Pilar Brito-Zerón^11,12, Munther A Khamashta¹³ and Manuel Ramos-Casals¹⁴, ¹Instituto de Investigaciones en Ciencias de la Salud, Universidad Nacional de Córdoba, Consejo Nacional de Investigaciones Científicas y Técnicas (INICSA-UNC-CONICET), Cordoba, Argentina, ²Laboratory of Systemic Autoimmune Diseases “Josep Font”, CELLEX, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Department of Systemic Autoimmune Diseases, ICMID, Hospital Clinic, Barcelona, Barcelona, Spain, ³Rheumatology Unit, Hospital Privado Universitario de Córdoba, Institute University of Biomedical Sciences University of Córdoba (IUCBC), Cordoba, Argentina, ⁴Department of Autoimmune Diseases, ICMiD, Hospital Clínic Barcelona, Spain., Barcelona, Spain, ⁵Unidad de Investigación Biomédica 02 (Unidad de Investigación en Epidemiología Clínica), UMAE, Hospital de Especialidades, Centro Médico Nacional de Occidente, Instituto Mexicano del Seguro Social, Jalisco, Mexico, ⁶Programa de Doctorado en Ciencias Médicas, Centro Universitario de Investigaciones Biomédicas (CUIB), Universidad de Colima, Colima, Mexico, Mexico, Mexico, ⁷ABS Les Corts, CAPSE, Research Group in Primary Care, IDIBAPS, ABS Les Corts, CAPSE, Barcelona, Spain, ⁸Primary Care Research Group, IDIBAPS, Centre d’Assistència Primària ABS Les Corts, GESCLINIC, Barcelona, Barcelona, Spain, ⁹Department of Anesthesia, Complexo Hospitalario Universitario A Coruña (CHUAC), A Coruña, Spain, ¹⁰Department of Internal Medicine, Hospital Alvaro Cunqueiro, Vigo, Vigo, Spain, ¹¹Autoimmune Diseases Unit, Department of Internal Medicine, Hospital CIMA-Sanitas, Barcelona, Barcelona, Spain, ¹²Department of Autoimmune Diseases, ICMiD, Hospital Clínic Barcelona, Barcelona, Spain, ¹³Lupus Research Unit, The Rayne Institute, Lupus Research Unit, The Rayne Institute, Kings' College London School of Medicine, St Thomas' Hospital, London, United Kingdom, ¹⁴Department of Autoimmune Diseases, ICMiD, Hospital Clínic Barcelona., Barcelona, Spain
Background/Purpose: The scenario of biological-triggered autoimmune diseases has dramatically changed in recent years due to the increasing use of biologics in patients with solid cancers. Methods:…
Abstract Number: 2167 • 2018 ACR/ARHP Annual Meeting
Incidence and Baseline Characteristics of Exacerbation in Patients with Interstitial Pneumonia with Autoimmune Features: A Single Center Large-Scale Cross-Sectional Cohort Study
Okinori Murata, Nobuhito Sasaki and Makoto Maemondo, Division of Pulmonary medicine, Allergy, and Rheumatology, Department of Internal Medicine, Iwate Medical University School of Medicine, Morioka, Japan
Background/Purpose: Patients with idiopathic interstitial pneumonia (IIP) may have features of connective tissue diseases (CTDs). The term interstitial pneumonia with autoimmune features (IPAF) has been…
Abstract Number: 2256 • 2018 ACR/ARHP Annual Meeting
Rheumatic Diseases Associated with Neuromyelitis Optica Spectrum Disorders (NMOSD): Prevalence, Clinical, Laboratory and Imaging Characteristics
Milena Rodriguez Alvarez¹, Su Zhaz Leon¹, Fernando Cuascut², Naureen Kabani³, Joshy Pathiparampil³, Kristaq Koci⁴, Manjeet Bhamra⁵, Latoya Freeman⁴, Alexandra Kreps⁶, Justin Levinson⁶, Sophia Francis⁶, Vinodkumar Velayndhan⁶, Steve Xie⁷, Abhimanyu Amarnani⁶, Helen Valsamis⁸, Yaacov Anziska⁶, Ellen M. Ginzler⁹ and Isabel M. McFarlane⁹, ¹Rheumatology, SUNY Downstate, Brooklyn, NY, ²Neurology, SUNY Downstate, Brooklyn, NY, ³Internal Medicine, SUNY Downstate Medical Center, Brooklyn, NY, ⁴Medicine, SUNY Downstate Medical Center, Brooklyn, NY, ⁵Medicine, SUNY Downstate, Brooklyn, NY, ⁶SUNY Downstate, Brooklyn, NY, ⁷NYC Health + Hospitals Kings County, Brooklyn, NY, ⁸Neurology, NYC Health + Hospitals Kings County, Brooklyn, NY, ⁹Rheumatology, SUNY Downstate Medical Center, Brooklyn, NY
Background/Purpose: NMOSD are autoimmune disorders characterized by optic neuritis (ON), longitudinal extensive transverse myelitis (LETM), and other clinical features. Aquaporin 4 antibodies (AQP4 Ab) have…
Abstract Number: 2257 • 2018 ACR/ARHP Annual Meeting
Prevalence and Distinct Clinical Phenotype of Concomitant Sarcoidosis in Other Autoimmune Rheumatic Diseases
Kristina E.N. Clark¹, Huw Beynon², Christopher P. Denton³ and Voon H. Ong⁴, ¹Centre of Rheumatology and Connective Tissue Diseases, University College London, London, United Kingdom, ²Department of Rheumatology, Royal Free Hospital, London, United Kingdom, ³UCL Division of Medicine, Royal Free Campus, London, United Kingdom, ⁴Division of Medicine, University College London, London, United Kingdom
Background/Purpose: Lung involvement is common in both sarcoidosis (up to 90%) and autoimmune rheumatic diseases (ARDs). Case reports have suggested distinct clinical manifestations when sarcoidosis…
Abstract Number: 2972 • 2018 ACR/ARHP Annual Meeting
Multicentric Reticulohistiocytosis (1980-2017): A Rare Disease, Commonly Associated with Malignancy and Autoimmunity
Avneek Singh Sandhu¹, Cynthia S. Crowson², David Wetter³, Gavin McKenzie⁴ and Ashima Makol¹, ¹Rheumatology, Mayo Clinic, Rochester, MN, ²Health Sciences Research, Mayo Clinic College of Medicine and Science, Rochester, MN, ³Dermatology, Mayo Clinic, Rochester, MN, ⁴Radiology, Mayo Clinic, Rochester, MN
Background/Purpose: Multicentric reticulohistiocytosis (MRH) is a systemic disease characterized by papulo-nodular skin eruptions and progressive, deforming arthritis. We aimed to examine the clinical correlates and…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].